Loading…
Sales and distribution affiliate of Celltrion Group, marketing generic and branded pharmaceuticals in the Korean market.
Sales and distribution affiliate of Celltrion Group, marketing generic and branded pharmaceuticals in the Korean market.
Moat: none (distribution). Domestic sales arm within Celltrion Group; limited differentiation versus other generics distributors.
Headquarters: Cheongju, South Korea
Size Celltrion Pharm (068760.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $1.27B, the 200th largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩39,600 on 6 Nov 2026.
Performance Over six months the shares fell 29.4%, against -9.0% for the median peer and -24.5% for the South Korea market (cap-weighted) — 5th lowest of 21 in its peer set.
Growth Revenue grew 13.9% over the last twelve months (peer median +6.3%); the operating margin is 10.7% (peer median 0.8%).
Valuation It trades at 3.0× enterprise value to sales against a peer median of 5.0× (5th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about 12% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is -6 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 3.1 points above its cost of capital (6.3% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩578B | ₩536B | ₩478B | ₩389B | ₩386B |
| Revenue growth | — | +12% | +23% | +1% | — |
| Gross profit | ₩175B | ₩161B | ₩118B | ₩117B | ₩112B |
| EBITDA | ₩85.5B | ₩78.4B | ₩57.3B | ₩55.7B | ₩55.6B |
| Net income | ₩42.9B | ₩38.8B | ₩22.0B | ₩21.3B | ₩26.0B |
| Free cash flow | ₩46.9B | ₩66.6B | ₩45.9B | -₩3.14B | -₩13.1B |
| Capital expenditure | ₩15.8B | ₩17.9B | ₩5.98B | ₩6.90B | ₩6.29B |
| Total debt | ₩160B | ₩161B | ₩172B | ₩163B | ₩161B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Celltrion Pharm 068760.KS | $1.27B | -29% | +14% | 11% | 3.0× | 11.7% |
| Celltrion 068270.KS | $34.3B | +10% | +40% | 32% | 8.6× | 8.3% |
| Yuhan 000100.KS | $4.05B | -12% | +5% | 5% | 2.4× | 20.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 068760.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.2% | -5.4% | 9th highest of 21 |
| 6-month return | -29.4% | -9.0% | 5th lowest of 21 |
| Distance from 52-week high | -49.4% | -38.0% | 7th lowest of 21 |
| Revenue growth (TTM) | +13.9% | +6.3% | 8th highest of 17 |
| Operating margin | 10.7% | 0.8% | 6th highest of 18 |
| EV / Sales | 3.0× | 5.0× | 5th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | 11.7% | 3.6% | most demanding of 7 |
| Growth delivered (Del g) | +18.1% | +6.3% | 2nd highest of 7 |
| Hurdle (Req g minus delivered) | -6.4 pp | -5.3 pp | 4th least demanding of 7 |
| ROIC minus cost of capital | +3.1 pp | -10.7 pp | 3rd highest of 19 |
| EV / EBITDA | 20.5× | 10.6× | 2nd most expensive of 4 |
| Net debt / EBITDA | 0.4× | 4.0× | 2nd least indebted of 5 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Celltrion Pharm 068760.KS | South Korea | $1.27B | -29% | +14% | 11% | 3.0× | 11.7% | +18.1% |
| Nektar Therapeutics NKTR | United States | $1.27B | -54% | -27% | -239% | 13.3× | n/a | n/a |
| OliX Pharmaceuticals 226950.KS | South Korea | $1.26B | -57% | +81% | -305% | 111.4× | n/a | n/a |
| GH Research GHRS | United States | $1.28B | -13% | n/a | n/a | n/a | n/a | n/a |
| D&D Pharmatech 347850.KS | South Korea | $1.28B | -49% | -71% | -1,368% | 617.6× | n/a | n/a |
| MannKind MNKD | United States | $1.25B | +11% | +30% | 3% | 4.0× | n/a | n/a |
| PYC Therapeutics PYC.AX | Australia | $1.28B | +31% | n/a | n/a | n/a | n/a | n/a |
| Avalyn Pharma AVLN | United States | $1.29B | +7% | n/a | n/a | n/a | n/a | n/a |
| Voronoi 310210.KS | South Korea | $1.31B | -66% | +24% | -1,947% | 417.6× | n/a | n/a |
| Sinopep-Allsino Bio Pharmaceutical 688076.SS | China | $1.31B | -7% | +14% | 19% | 5.0× | 4.0% | +27.9% |
| Omeros OMER | United States | $1.22B | +14% | n/a | -190% | 36.2× | n/a | n/a |
| Everest Medicines 1952.HK | Hong Kong | $1.22B | -20% | +193% | -5% | 3.5× | n/a | n/a |
| C.Q. Pharmaceutical 000950.SZ | China | $1.32B | -12% | -3% | 1% | 0.5× | n/a | n/a |
| Amphastar Pharmaceuticals AMPH | United States | $1.21B | +50% | +1% | 16% | 2.2× | 3.3% | +15.5% |
| Tianjin Chase Sun Pharmaceutical 300026.SZ | China | $1.32B | -6% | -29% | 3% | 2.0× | 8.5% | -5.3% |
| Changzhou Qianhong Bio-Pharma 002550.SZ | China | $1.21B | -8% | -2% | 15% | 4.5× | 4.5% | -1.2% |
| Hanall Biopharma 009420.KS | South Korea | $1.34B | -25% | +5% | 3% | 11.2× | n/a | n/a |
| Lotus Pharmaceutical 1795.TW | Taiwan | $1.34B | -26% | +49% | 24% | 3.4× | -2.4% | +13.8% |
| Idorsia IDIA.SW | Switzerland | $1.34B | -5% | -5% | -70% | 10.7× | n/a | n/a |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.34B | +2% | +8% | 11% | 2.1× | 0.3% | -1.3% |
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.34B | -10% | +256% | -27% | 10.0× | n/a | n/a |